Annual Cash & Cash Equivalents
$84.58 M
+$8.38 M+11.00%
December 31, 2023
Summary
- As of February 7, 2025, PBYI annual cash & cash equivalents is $84.58 million, with the most recent change of +$8.38 million (+11.00%) on December 31, 2023.
- During the last 3 years, PBYI annual cash & cash equivalents has fallen by -$708.00 thousand (-0.83%).
- PBYI annual cash & cash equivalents is now -56.51% below its all-time high of $194.49 million, reached on December 31, 2016.
Performance
PBYI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$67.26 M
+$114.00 K+0.17%
September 30, 2024
Summary
- As of February 7, 2025, PBYI quarterly cash and cash equivalents is $67.26 million, with the most recent change of +$114.00 thousand (+0.17%) on September 30, 2024.
- Over the past year, PBYI quarterly cash and cash equivalents has dropped by -$14.54 million (-17.77%).
- PBYI quarterly cash and cash equivalents is now -65.42% below its all-time high of $194.49 million, reached on December 31, 2016.
Performance
PBYI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PBYI Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +11.0% | -17.8% |
| 3 y3 years | -0.8% | +27.5% |
| 5 y5 years | -22.0% | +27.5% |
PBYI Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +34.0% | -20.5% | +27.5% |
| 5 y | 5-year | -0.8% | +40.9% | -29.7% | +27.5% |
| alltime | all time | -56.5% | >+9999.0% | -65.4% | -100.0% |
Puma Biotechnology Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $67.26 M(+0.2%) |
| Jun 2024 | - | $67.15 M(-12.5%) |
| Mar 2024 | - | $76.75 M(-9.3%) |
| Dec 2023 | $84.58 M(+11.0%) | $84.58 M(+3.4%) |
| Sep 2023 | - | $81.80 M(+36.3%) |
| Jun 2023 | - | $60.01 M(-2.3%) |
| Mar 2023 | - | $61.39 M(-19.4%) |
| Dec 2022 | $76.20 M(+20.7%) | $76.20 M(-2.3%) |
| Sep 2022 | - | $77.96 M(+47.8%) |
| Jun 2022 | - | $52.76 M(-17.5%) |
| Mar 2022 | - | $63.91 M(+1.2%) |
| Dec 2021 | $63.13 M(-26.0%) | $63.13 M(-1.3%) |
| Sep 2021 | - | $63.95 M(-28.8%) |
| Jun 2021 | - | $89.85 M(-6.1%) |
| Mar 2021 | - | $95.65 M(+12.1%) |
| Dec 2020 | $85.29 M(+42.1%) | $85.29 M(-5.3%) |
| Sep 2020 | - | $90.08 M(-0.9%) |
| Jun 2020 | - | $90.90 M(+9.0%) |
| Mar 2020 | - | $83.39 M(+38.9%) |
| Dec 2019 | $60.04 M(-44.6%) | $60.04 M(+1.9%) |
| Sep 2019 | - | $58.90 M(+116.8%) |
| Jun 2019 | - | $27.16 M(-44.3%) |
| Mar 2019 | - | $48.79 M(-55.0%) |
| Dec 2018 | $108.42 M(+32.7%) | $108.42 M(+58.7%) |
| Sep 2018 | - | $68.30 M(-28.8%) |
| Jun 2018 | - | $95.91 M(+22.1%) |
| Mar 2018 | - | $78.55 M(-3.9%) |
| Dec 2017 | $81.70 M(-58.0%) | $81.70 M(+2.5%) |
| Sep 2017 | - | $79.72 M(-1.4%) |
| Jun 2017 | - | $80.82 M(-23.1%) |
| Mar 2017 | - | $105.09 M(-46.0%) |
| Dec 2016 | $194.49 M | $194.49 M(+270.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $52.54 M(-9.2%) |
| Jun 2016 | - | $57.84 M(-26.1%) |
| Mar 2016 | - | $78.22 M(+147.8%) |
| Dec 2015 | $31.57 M(-18.1%) | $31.57 M(+33.8%) |
| Sep 2015 | - | $23.60 M(-60.6%) |
| Jun 2015 | - | $59.84 M(-61.5%) |
| Mar 2015 | - | $155.47 M(+303.4%) |
| Dec 2014 | $38.54 M(-10.5%) | $38.54 M(+36.4%) |
| Sep 2014 | - | $28.26 M(-48.9%) |
| Jun 2014 | - | $55.36 M(-66.1%) |
| Mar 2014 | - | $163.38 M(+279.6%) |
| Dec 2013 | $43.04 M(-68.7%) | $43.04 M(-16.0%) |
| Sep 2013 | - | $51.26 M(-15.8%) |
| Jun 2013 | - | $60.90 M(-33.5%) |
| Mar 2013 | - | $91.65 M(-33.3%) |
| Dec 2012 | $137.41 M(+157.4%) | $137.41 M(+312.1%) |
| Sep 2012 | - | $33.35 M(-18.7%) |
| Jun 2012 | - | $41.00 M(-18.3%) |
| Mar 2012 | - | $50.17 M(-6.0%) |
| Dec 2011 | $53.38 M(>+9900.0%) | $53.38 M(>+9900.0%) |
| Sep 2011 | - | $0.00(-100.0%) |
| Jun 2011 | - | $1700.00(+750.0%) |
| Mar 2011 | - | $200.00(-60.0%) |
| Dec 2010 | $500.00(-79.2%) | $500.00(-76.2%) |
| Sep 2010 | - | $2100.00(+16.7%) |
| Jun 2010 | - | $1800.00(>+9900.0%) |
| Mar 2010 | - | $0.00(-100.0%) |
| Dec 2009 | $2400.00(+2300.0%) | $2400.00(+2300.0%) |
| Sep 2009 | - | $100.00(-95.8%) |
| Jun 2009 | - | $2400.00(+2300.0%) |
| Mar 2009 | - | $100.00(0.0%) |
| Dec 2008 | $100.00 | $100.00 |
FAQ
- What is Puma Biotechnology annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Puma Biotechnology?
- What is Puma Biotechnology annual cash & cash equivalents year-on-year change?
- What is Puma Biotechnology quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Puma Biotechnology?
- What is Puma Biotechnology quarterly cash and cash equivalents year-on-year change?
What is Puma Biotechnology annual cash & cash equivalents?
The current annual cash & cash equivalents of PBYI is $84.58 M
What is the all time high annual cash & cash equivalents for Puma Biotechnology?
Puma Biotechnology all-time high annual cash & cash equivalents is $194.49 M
What is Puma Biotechnology annual cash & cash equivalents year-on-year change?
Over the past year, PBYI annual cash & cash equivalents has changed by +$8.38 M (+11.00%)
What is Puma Biotechnology quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PBYI is $67.26 M
What is the all time high quarterly cash and cash equivalents for Puma Biotechnology?
Puma Biotechnology all-time high quarterly cash and cash equivalents is $194.49 M
What is Puma Biotechnology quarterly cash and cash equivalents year-on-year change?
Over the past year, PBYI quarterly cash and cash equivalents has changed by -$14.54 M (-17.77%)